

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 June 2009 (18.06.2009)

PCT

(10) International Publication Number
WO 2009/074782 A1

(51) International Patent Classification:

C07D 231/14 (2006.01) **C07D 413/06** (2006.01)
C07D 401/12 (2006.01) **A61K 31/415** (2006.01)
C07D 401/14 (2006.01) **A61K 31/4155** (2006.01)
C07D 403/04 (2006.01) **A61P 3/04** (2006.01)

(21) International Application Number:

PCT/GB2008/004051

(22) International Filing Date:

8 December 2008 (08.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0724096.3 10 December 2007 (10.12.2007) GB
0813350.6 21 July 2008 (21.07.2008) GB

(71) Applicant (for all designated States except US): **7TM PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2970 Hoersholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RECEVEUR, Jean Marie** [FR/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **BJURLING, Emelie** [SE/SE]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **MURRAY, Anthony** [GB/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK).

HOEGBERG, Thomas [SE/SE]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **NEILSEN, Peter, Aadal** [DK/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **LINGET, Jean-Michel** [FR/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **NOERREGAARD, Pia, Karina** [DK/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK). **ALMHOLT, Dorthie** [DK/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK).


(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth, Surrey KT20 5YF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,

[Continued on next page]

(54) Title: CANNABINOID RECEPTOR MODULATORS



(57) Abstract: Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from -C(R₁₀)(R₁₁)-*, -C(R₁₀)(R₁₁)-O-*, -C(R₁₀)(R₁₁)CH₂-, -C(R₁₀)(R₁₁)CH₂-O-*, -CH₂C(R₁₀)(R₁₁)-*, -CH₂C(R₁₀)(R₁₁)-O-*, and -CH₂-O-C(R₁₀)(R₁₁)-*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R₃ is hydrogen, (C₁-C₃)alkyl or (C₁C₃)fluoroalkyl; R₄ is a radical of formula -(Alk₁)_p-(Q₁)_r-(L)_s-Q₂ wherein p, r, s, Alk₁, L, Q₁ and Q₂ are as specified; or R₃ and R₄ taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L)_s-Q₂ wherein s, L and Q₂ are as defined above, or by an optional substituent selected from hydroxy, methoxy, -NH₂-, or mono- or di-(C₁C₃)alkylamino; R₅, R₆, R₇ and R₈ are each independently selected from hydrogen, -F, -Cl, -Br, -CN, (C₁-C₃)alkyl, (C₁C₃)fluoroalkyl, cyclopropyl, and -OR₉; R₁₀ is hydrogen, (C₁C₃)alkyl, hydroxyl or NH₂, and R₁₁ is hydrogen or (C₁-C₃)alkyl; or R₁₀ and R₁₁ taken together with the carbon atom to which they are attached form a (C₃-C₅)cycloalkyl ring.



NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*